Isocitrate dehydrogenase (IDH) (EC 1.1.1.42) and (EC 1.1.1.41) is an enzyme that catalyzes the oxidative decarboxylation of isocitrate, producing alpha-ketoglutarate (α-ketoglutarate) and CO2.
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
Market Analysis and Insights: Global Isocitrate Dehydrogenase Inhibitors Market
The research report studies the Isocitrate Dehydrogenase Inhibitors market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Isocitrate Dehydrogenase Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Isocitrate Dehydrogenase Inhibitors Scope and Segment
The global Isocitrate Dehydrogenase Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Isocitrate Dehydrogenase Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
by Application, this report covers the following segments
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
Global Isocitrate Dehydrogenase Inhibitors market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Isocitrate Dehydrogenase Inhibitors key players in this market include:
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
Specific mutations in the isocitrate dehydrogenase gene IDH1 have been found in several brain tumors including astrocytoma, oligodendroglioma and glioblastoma multiforme, with mutations found in nearly all cases of secondary glioblastomas, which develop from lower-grade gliomas, but rarely in primary high-grade glioblastoma multiforme.Patients whose tumor had an IDH1 mutation had longer survival. Furthermore, mutations of IDH2 and IDH1 were found in up to 20% of cytogenetically normal acute myeloid leukemia (AML).These mutations are known to produce (D)-2-hydroxyglutarate from alpha-ketoglutarate.(D)-2-hydroxyglutarate accumulates to very high concentrations which inhibits the function of enzymes that are dependent on alpha-ketoglutarate.This leads to a hypermethylated state of DNA and histones, which results in different gene expression that can activate oncogenes and inactivate tumor-suppressor genes. Ultimately, this may lead to the types of cancer described above.Isocitrate dehydrogenase inhibition technology can be effectively applied to the cancer market.
Market Analysis and Insights: Global Isocitrate Dehydrogenase Inhibitors Market
The research report studies the Isocitrate Dehydrogenase Inhibitors market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Isocitrate Dehydrogenase Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Isocitrate Dehydrogenase Inhibitors Scope and Segment
The global Isocitrate Dehydrogenase Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Isocitrate Dehydrogenase Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
IDH1 Mutant Medullary Malignant Tumor
IDH2 Mutant Medullary Malignant Tumor
Others
by Application, this report covers the following segments
DH Inhibitor
FLT3 Inhibitor
Hedgehog Pathway Inhibitor
Others
Global Isocitrate Dehydrogenase Inhibitors market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Isocitrate Dehydrogenase Inhibitors key players in this market include:
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen
1 Market Overview of Isocitrate Dehydrogenase Inhibitors
1.1 Isocitrate Dehydrogenase Inhibitors Market Overview
1.1.1 Isocitrate Dehydrogenase Inhibitors Product Scope
1.1.2 Market Status and Outlook
1.2 Global Isocitrate Dehydrogenase Inhibitors Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Isocitrate Dehydrogenase Inhibitors Market Size by Region (2015-2026)
1.4 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Region (2015-2020)
1.5 Global Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.1 North America Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.2 Europe Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.4 Latin America Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
2 Isocitrate Dehydrogenase Inhibitors Market Overview by Type
2.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Type (2015-2020)
2.3 Global Isocitrate Dehydrogenase Inhibitors Forecasted Market Size by Type (2021-2026)
2.4 IDH1 Mutant Medullary Malignant Tumor
2.5 IDH2 Mutant Medullary Malignant Tumor
2.6 Others
3 Isocitrate Dehydrogenase Inhibitors Market Overview by Application
3.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Application (2015-2020)
3.3 Global Isocitrate Dehydrogenase Inhibitors Forecasted Market Size by Application (2021-2026)
3.4 DH Inhibitor
3.5 FLT3 Inhibitor
3.6 Hedgehog Pathway Inhibitor
3.7 Others
4 Global Isocitrate Dehydrogenase Inhibitors Competition Analysis by Players
4.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Isocitrate Dehydrogenase Inhibitors as of 2019)
4.3 Date of Key Manufacturers Enter into Isocitrate Dehydrogenase Inhibitors Market
4.4 Global Top Players Isocitrate Dehydrogenase Inhibitors Headquarters and Area Served
4.5 Key Players Isocitrate Dehydrogenase Inhibitors Product Solution and Service
4.6 Competitive Status
4.6.1 Isocitrate Dehydrogenase Inhibitors Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 AGIOS
5.1.1 AGIOS Profile
5.1.2 AGIOS Main Business
5.1.3 AGIOS Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.1.4 AGIOS Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.1.5 AGIOS Recent Developments
5.2 Aslan Pharmaceuticals
5.2.1 Aslan Pharmaceuticals Profile
5.2.2 Aslan Pharmaceuticals Main Business
5.2.3 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.2.4 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.2.5 Aslan Pharmaceuticals Recent Developments
5.3 Bayer
5.5.1 Bayer Profile
5.3.2 Bayer Main Business
5.3.3 Bayer Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.3.4 Bayer Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.3.5 Beigene Recent Developments
5.4 Beigene
5.4.1 Beigene Profile
5.4.2 Beigene Main Business
5.4.3 Beigene Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.4.4 Beigene Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.4.5 Beigene Recent Developments
5.5 Bristol-Myers Squibb
5.5.1 Bristol-Myers Squibb Profile
5.5.2 Bristol-Myers Squibb Main Business
5.5.3 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.5.4 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.5.5 Bristol-Myers Squibb Recent Developments
5.6 Celgene
5.6.1 Celgene Profile
5.6.2 Celgene Main Business
5.6.3 Celgene Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.6.4 Celgene Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.6.5 Celgene Recent Developments
5.7 Daiichi Sankyo
5.7.1 Daiichi Sankyo Profile
5.7.2 Daiichi Sankyo Main Business
5.7.3 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.7.4 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.7.5 Daiichi Sankyo Recent Developments
5.8 Philogen S.p.A.
5.8.1 Philogen S.p.A. Profile
5.8.2 Philogen S.p.A. Main Business
5.8.3 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.8.4 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.8.5 Philogen S.p.A. Recent Developments
5.9 Tesaro
5.9.1 Tesaro Profile
5.9.2 Tesaro Main Business
5.9.3 Tesaro Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.9.4 Tesaro Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.9.5 Tesaro Recent Developments
5.10 Tragara/Adastra
5.10.1 Tragara/Adastra Profile
5.10.2 Tragara/Adastra Main Business
5.10.3 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.10.4 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.10.5 Tragara/Adastra Recent Developments
5.11 Tocagen
5.11.1 Tocagen Profile
5.11.2 Tocagen Main Business
5.11.3 Tocagen Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.11.4 Tocagen Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.11.5 Tocagen Recent Developments
6 North America
6.1 North America Isocitrate Dehydrogenase Inhibitors Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Isocitrate Dehydrogenase Inhibitors Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Isocitrate Dehydrogenase Inhibitors Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Isocitrate Dehydrogenase Inhibitors Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Isocitrate Dehydrogenase Inhibitors Market Overview
1.1.1 Isocitrate Dehydrogenase Inhibitors Product Scope
1.1.2 Market Status and Outlook
1.2 Global Isocitrate Dehydrogenase Inhibitors Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global Isocitrate Dehydrogenase Inhibitors Market Size by Region (2015-2026)
1.4 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Region (2015-2020)
1.5 Global Isocitrate Dehydrogenase Inhibitors Market Size Forecast by Region (2021-2026)
1.6 Key Regions, Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.1 North America Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.2 Europe Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.4 Latin America Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size YoY Growth (2015-2026)
2 Isocitrate Dehydrogenase Inhibitors Market Overview by Type
2.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Type (2015-2020)
2.3 Global Isocitrate Dehydrogenase Inhibitors Forecasted Market Size by Type (2021-2026)
2.4 IDH1 Mutant Medullary Malignant Tumor
2.5 IDH2 Mutant Medullary Malignant Tumor
2.6 Others
3 Isocitrate Dehydrogenase Inhibitors Market Overview by Application
3.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global Isocitrate Dehydrogenase Inhibitors Historic Market Size by Application (2015-2020)
3.3 Global Isocitrate Dehydrogenase Inhibitors Forecasted Market Size by Application (2021-2026)
3.4 DH Inhibitor
3.5 FLT3 Inhibitor
3.6 Hedgehog Pathway Inhibitor
3.7 Others
4 Global Isocitrate Dehydrogenase Inhibitors Competition Analysis by Players
4.1 Global Isocitrate Dehydrogenase Inhibitors Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Isocitrate Dehydrogenase Inhibitors as of 2019)
4.3 Date of Key Manufacturers Enter into Isocitrate Dehydrogenase Inhibitors Market
4.4 Global Top Players Isocitrate Dehydrogenase Inhibitors Headquarters and Area Served
4.5 Key Players Isocitrate Dehydrogenase Inhibitors Product Solution and Service
4.6 Competitive Status
4.6.1 Isocitrate Dehydrogenase Inhibitors Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 AGIOS
5.1.1 AGIOS Profile
5.1.2 AGIOS Main Business
5.1.3 AGIOS Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.1.4 AGIOS Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.1.5 AGIOS Recent Developments
5.2 Aslan Pharmaceuticals
5.2.1 Aslan Pharmaceuticals Profile
5.2.2 Aslan Pharmaceuticals Main Business
5.2.3 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.2.4 Aslan Pharmaceuticals Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.2.5 Aslan Pharmaceuticals Recent Developments
5.3 Bayer
5.5.1 Bayer Profile
5.3.2 Bayer Main Business
5.3.3 Bayer Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.3.4 Bayer Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.3.5 Beigene Recent Developments
5.4 Beigene
5.4.1 Beigene Profile
5.4.2 Beigene Main Business
5.4.3 Beigene Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.4.4 Beigene Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.4.5 Beigene Recent Developments
5.5 Bristol-Myers Squibb
5.5.1 Bristol-Myers Squibb Profile
5.5.2 Bristol-Myers Squibb Main Business
5.5.3 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.5.4 Bristol-Myers Squibb Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.5.5 Bristol-Myers Squibb Recent Developments
5.6 Celgene
5.6.1 Celgene Profile
5.6.2 Celgene Main Business
5.6.3 Celgene Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.6.4 Celgene Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.6.5 Celgene Recent Developments
5.7 Daiichi Sankyo
5.7.1 Daiichi Sankyo Profile
5.7.2 Daiichi Sankyo Main Business
5.7.3 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.7.4 Daiichi Sankyo Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.7.5 Daiichi Sankyo Recent Developments
5.8 Philogen S.p.A.
5.8.1 Philogen S.p.A. Profile
5.8.2 Philogen S.p.A. Main Business
5.8.3 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.8.4 Philogen S.p.A. Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.8.5 Philogen S.p.A. Recent Developments
5.9 Tesaro
5.9.1 Tesaro Profile
5.9.2 Tesaro Main Business
5.9.3 Tesaro Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.9.4 Tesaro Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.9.5 Tesaro Recent Developments
5.10 Tragara/Adastra
5.10.1 Tragara/Adastra Profile
5.10.2 Tragara/Adastra Main Business
5.10.3 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.10.4 Tragara/Adastra Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.10.5 Tragara/Adastra Recent Developments
5.11 Tocagen
5.11.1 Tocagen Profile
5.11.2 Tocagen Main Business
5.11.3 Tocagen Isocitrate Dehydrogenase Inhibitors Products, Services and Solutions
5.11.4 Tocagen Isocitrate Dehydrogenase Inhibitors Revenue (US$ Million) & (2015-2020)
5.11.5 Tocagen Recent Developments
6 North America
6.1 North America Isocitrate Dehydrogenase Inhibitors Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Isocitrate Dehydrogenase Inhibitors Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Isocitrate Dehydrogenase Inhibitors Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Isocitrate Dehydrogenase Inhibitors Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Isocitrate Dehydrogenase Inhibitors Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Isocitrate Dehydrogenase Inhibitors Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
